Profile data is unavailable for this security.
About the company
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.
- Revenue in GBP (TTM)0.00
- Net income in GBP-22.40m
- Incorporated2006
- Employees25.00
- LocationFaron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
- Phone+358 24695151
- Fax+358 24695152
- Websitehttps://www.faron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| hVIVO PLC | 62.73m | 10.65m | 69.73m | 301.00 | 6.56 | 1.55 | 4.91 | 1.11 | 0.0155 | 0.0155 | 0.0911 | 0.0657 | 0.7289 | -- | 4.20 | 208,388.70 | 12.38 | 5.51 | 20.28 | 10.35 | -- | -- | 16.98 | 6.73 | 1.86 | -- | 0.2241 | 67.09 | 11.92 | 79.44 | -33.90 | -- | 154.59 | -- |
| Scancell Holdings Plc | 0.00 | -15.81m | 107.31m | 61.00 | -- | -- | -- | -- | -0.0171 | -0.0171 | 0.00 | -0.015 | 0.00 | -- | -- | 0.00 | -81.40 | -31.66 | -625.06 | -37.66 | -- | -- | -- | -822.37 | -- | -42.23 | 251.00 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
| Avacta Group Plc | 11.26m | -29.43m | 132.50m | 151.00 | -- | 13.63 | -- | 11.77 | -0.085 | -0.1496 | 0.0327 | 0.0251 | 0.1854 | 0.00 | 2.64 | 74,576.16 | -48.46 | -43.48 | -172.33 | -78.27 | 44.59 | 63.54 | -261.32 | -781.44 | 1.08 | -0.5712 | 0.7229 | -- | -96.04 | -- | -0.9503 | -- | -- | -- |
| Bioventix PLC | 13.66m | 7.85m | 142.38m | 17.00 | 18.40 | 12.61 | 17.90 | 10.42 | 1.48 | 1.48 | 2.58 | 2.16 | 1.04 | 2.17 | 2.21 | 803,738.30 | 59.98 | 58.33 | 69.06 | 63.62 | 90.95 | 93.09 | 57.42 | 64.12 | 6.69 | -- | 0.00 | 90.92 | 6.17 | 7.93 | -3.29 | 6.67 | -28.40 | 16.25 |
| 4Basebio PLC | 933.00k | -12.33m | 152.77m | -- | -- | 5.78 | -- | 163.74 | -0.9391 | -0.9391 | 0.0711 | 1.70 | 0.0329 | 0.8584 | 4.78 | -- | -43.54 | -36.81 | -48.26 | -40.98 | 67.52 | 69.88 | -1,321.87 | -1,160.83 | 11.18 | -19.68 | 0.3658 | -- | 84.39 | 35.80 | -60.90 | -- | 50.57 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -22.40m | 228.84m | 25.00 | -- | -- | -- | -- | -0.2677 | -0.2677 | 0.00 | -0.0807 | 0.00 | -- | -- | 0.00 | -227.96 | -227.46 | -- | -1,738.54 | -- | -- | -- | -- | -- | -2.58 | 5.15 | -- | -- | -- | 16.24 | -- | 17.71 | -- |
| Puretech Health PLC | 3.60m | 39.89m | 334.23m | 56.00 | 7.82 | 1.08 | 14.30 | 92.87 | 0.1775 | 0.1775 | 0.0141 | 1.29 | 0.0075 | -- | 2.48 | 64,266.71 | 4.29 | -3.27 | 4.57 | -3.83 | -- | -- | 575.43 | -253.25 | -- | -- | 0.052 | -- | 44.98 | -13.21 | 181.45 | -33.81 | -75.53 | -- |
| Allergy Therapeutics plc | 55.66m | -35.65m | 381.32m | 602.00 | -- | -- | -- | 6.85 | -0.0075 | -0.0075 | 0.0117 | -0.0015 | 0.7836 | 2.15 | 6.00 | 92,453.49 | -50.19 | -22.88 | -78.92 | -30.15 | 54.04 | 66.47 | -64.05 | -24.88 | 1.15 | -4.07 | 1.19 | -- | -7.36 | -5.62 | 6.63 | -- | 1.88 | -- |
| Oxford BioMedica plc | 128.80m | -43.19m | 384.75m | 861.00 | -- | 6.73 | -- | 2.99 | -0.414 | -0.414 | 1.24 | 0.5384 | 0.5322 | 5.73 | 4.71 | 149,590.00 | -20.09 | -20.23 | -25.99 | -25.48 | 41.17 | 49.36 | -37.74 | -45.03 | 2.05 | -5.42 | 0.6426 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
Data as of Jul 18 2025. Currency figures normalised to Faron Pharmaceuticals Oy's reporting currency: UK Pound GBX
11.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 24 Jun 2024 | 4.60m | 4.11% |
| Fj�rde AP-fondenas of 06 Feb 2025 | 3.15m | 2.81% |
| OP Asset Management Ltd.as of 30 Jun 2024 | 2.68m | 2.39% |
| Sp-Fund Management Co. Ltd.as of 30 Jun 2025 | 1.58m | 1.41% |
| Danske Bank A/S (Investment Management Finland)as of 31 May 2024 | 431.72k | 0.39% |
| Fondita Fund Management Co. Ltd.as of 31 May 2024 | 330.49k | 0.30% |
| Canaccord Genuity Wealth Ltd.as of 30 Sep 2024 | 162.28k | 0.15% |
| Veikko Laine Oyas of 31 May 2024 | 148.00k | 0.13% |
| Janus Henderson Investors UK Ltd.as of 31 May 2025 | 100.00k | 0.09% |
| BG Fund Management Luxembourg SAas of 31 Dec 2024 | 46.79k | 0.04% |
More ▼
Data from 31 Jul 2024 - 30 Jun 2025Source: FactSet Research Systems Inc.
